Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
Overview
- Phase
- Phase 4
- Intervention
- Apomorphine
- Conditions
- Parkinson's Disease
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Difference between the Parkinson's disease sleeping disorders (PDSD-2) score before treatment with an apomorphine pump and 3 months after the beginning of the treatment
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
Parkinson's disease is not only a pathology of movements. There are many non-motor symptoms that complicate and impair patients' quality of life. Among those disorders are sleep disorders.
Insomnia is the most frequent symptom. Most patients report 2-5 awakenings per night and long periods of awakening which occupy 30 to 40% of their night.
Apomorphine is a dopamine agonist that may be administered with a pump . The objective of the study is to assess changes in the quality of sleep in Parkinson's disease patients treated with an apomorphine pump.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Parkinson's disease patients for whom a treatment with an apomorphine pump is indicated
Exclusion Criteria
- •atypical parkinsonian syndrome
- •cognitive impairment
- •pregnancy
- •breast feeding
- •patient under a legal protection procedure
- •patient denying to participate to the study
- •lack of affiliation to a social security system
Arms & Interventions
Apomorphine pump
Intervention: Apomorphine
Outcomes
Primary Outcomes
Difference between the Parkinson's disease sleeping disorders (PDSD-2) score before treatment with an apomorphine pump and 3 months after the beginning of the treatment
Time Frame: Three months